Neil A. Goldenberg

Neil A. Goldenberg

Auto-generated profile, based on publicly available information

Neil A. Goldenberg

Johns Hopkins All Children's Institute for Clinical and Translational Research, St. Petersburg, FL; Departments of Pediatrics; Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2022 in JAMA
Verified
Journal Article
Open access
PDF file
NGNeil A. Goldenberg
Neil A. Goldenberg
JKJohn M. Kittelson
John M. Kittelson
TAThomas C. Abshire
Thomas C. Abshire
MBMarc Bonaca
Marc Bonaca
JCJames F. Casella
James F. Casella
TGthe ATLAS Group
the ATLAS Group
Quiz Ref ID The evidence underlying use of anticoagulant therapy for venous thromboembolism stems from a randomized clinical trial (RCT) in the 1960s1 and subsequent uncontrolled studies demonstrating a reduction in the risk of recurrent venous thromboembolism. Recurrent venous thromboembolism encompasses deep vein thrombosis (DVT) and pulmonary embolism; recurrent DVT can increase the risk of chronic venous insufficiency (postthrombotic syndrome) and pulmonary embolism can be fatal.2,3 Anticoagulant therapy for venous thromboembolism involves a trade-off between risks of recurrent venous thromboembolism and bleeding. As a statistical model for this trade-off, Kittelson et al4-7 described a bivariate end point analytic approach, and applied this method to evaluate the net clinical benefit of antithrombotic therapies in RCTs.

23 July 2014 in The Journal of Pediatrics
Verified
Journal Article
Closed access
CAChristie M. Atchison
Christie M. Atchison
SAShilpa Arlikar
Shilpa Arlikar
EAErnest Amankwah
Ernest Amankwah
IAIrmel Ayala
Irmel Ayala
LBLaurie Barrett
Laurie Barrett
NGNeil A. Goldenberg
Neil A. Goldenberg

28 June 2015 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
NGN. A. Goldenberg
N. A. Goldenberg
TAT. Abshire
T. Abshire
PBP. J. Blatchford
P. J. Blatchford
LFL. Z. Fenton
L. Z. Fenton
JHJ. L. Halperin
J. L. Halperin
AZA. Zia
A. Zia
Background Randomized controlled trials (RCTs) on pediatric venous thromboembolism (VTE) treatment have been challenged by unsubstantiated design assumptions and/or poor accrual. Pilot/feasibility (P/F) studies are critical to future RCT success. Methods The Kids‐DOTT trial is a multicenter RCT investigating non‐inferiority of a 6‐week (shortened) versus 3‐month (conventional) duration of anticoagulation in patients aged < 21 years with provoked venous thrombosis. Primary efficacy and safety endpoints are symptomatic recurrent VTE at 1 year and anticoagulant‐related, clinically relevant bleeding. In the P/F phase, 100 participants were enrolled in an open, blinded‐endpoint, parallel‐cohort RCT design. Results No eligibility violations or randomization errors occurred. Of the enrolled patients, 69% were randomized, 3% missed the randomization window, and 28% were followed in prespecified observational cohorts for completely occlusive thrombosis or persistent antiphospholipid antibodies. Retention at 1 year was 82%. Interobserver agreement between local and blinded central determination of venous occlusion by imaging at 6 weeks after diagnosis was strong (k‐statistic = 0.75; 95% confidence interval [CI] 0.48–1.0). The primary efficacy and safety event rates were 3.3% (95% CI 0.3–11.5%) and 1.4% (95% CI 0.03–7.4%). Conclusions The P/F phase of the Kids‐DOTT trial has demonstrated the validity of vascular imaging findings of occlusion as a randomization criterion, and defined randomization, retention and endpoint rates to inform the fully powered RCT.

1 October 2015 in Thrombosis Research
Verified
Journal Article
Closed access
SAShilpa J. Arlikar
Shilpa J. Arlikar
CAChristie M. Atchison
Christie M. Atchison
EAErnest K. Amankwah
Ernest K. Amankwah
IAIrmel A. Ayala
Irmel A. Ayala
LBLaurie A. Barrett
Laurie A. Barrett
NGNeil A. Goldenberg
Neil A. Goldenberg

10 September 2020 in The Journal of Pediatrics
Verified
Journal Article
Closed access
JJJulie Jaffray
Julie Jaffray
BBBrian Branchford
Brian Branchford
NGNeil Goldenberg
Neil Goldenberg
JMJemily Malvar
Jemily Malvar
SCStacy E. Croteau
Stacy E. Croteau
AMArash Mahajerin
Arash Mahajerin